Chimeric antigen receptor T-cell (CAR T) immunotherapy opens a new path for targeted therapy of hematological malignancies. In this review, through a representative case study, we summarize the current experience of CAR T-cell therapy, the management of common side effects, the causative mechanisms...
A phase 1 trial of PSCA-targeting CAR T cell therapy in patients with PSCA-positive, metastatic castration-resistant prostate cancer demonstrates that the treatment, using a protocol with reduced lymphodepletion, is safe and shows preliminary clinical activity. ...
嵌合抗原受体细胞免疫疗法(Chimeric Antigen Receptor T-Cell Immunotherapy)简称CAR-T疗法,是指人为改变T细胞表面的抗体,使其既能特异性识别肿瘤细胞,又能激活T细胞,然后再利用此细胞消灭肿瘤。2016年12月,某研究团队公布,他们利用CAR-T疗法治愈了一例复发性多灶胶质母细胞瘤,为人类攻克癌症带来曙光。 CAR-T疗法流程...
Cancer cell reprogramming: turning the enemy into an ally Severin Guetter Kaiji Fan Hendrik Poeck Research HighlightsOpen Access17 Jan 2025Signal Transduction and Targeted Therapy Volume: 10, P: 13 Past interactions of T cells with antigens shape CAR T cell responses ...
Chimeric antigen receptor (CAR) T cell therapy, in which a patient’s own T lymphocytes are engineered to recognize and kill cancer cells, has achieved striking success in some hematological malignancies in preclinical and clinical trials, resulting in s
In recent decades, immune checkpoint blockade and chimeric antigen receptor T cell (CAR-T) therapy are two milestone achievements in clinical immunotherapy. However, both show limited efficacies in most solid neoplasms, which necessitates the exploration
Adoptive T cell transfer (ACT) is a new area of transfusion medicine involving the infusion of lymphocytes to mediate antitumor, antiviral, or anti-inflammatory effects. The field has rapidly advanced from a promising form of immuno-oncology in preclinical models to the recent commercial approvals...
CAR-T(全称Chimeric Antigen Receptor T-Cell Immunotherapy)是嵌合抗原受体T细胞免疫疗法的英文缩写。()A.正确B.错
CAR T-cell therapy: the latest weapon in the fight against cancer Read our blog post examining how CAR T-cell therapies for blood cancers show promise for a safer, targeted, and more effective cancer treatment. Learn more Featured products ...
It forms part of a new line of immune-boosting CAR T cell therapy treatments, which take a patient's own immune cells and modify them in a lab before reintroducing them into the body. Gregor McNie, Cancer Research UK's head of external relations in Scotland, called the rejection "disappoi...